Halozyme Therapeutics, Inc. income statement

In fiscal 2025, Halozyme Therapeutics, Inc. reported revenue of $1.40bn, up 37.6% on the year before, operating income of $469m (a 33.6% margin) and net income of $317m, or $2.56 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Halozyme Therapeutics, Inc.: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	14	14	56	42	55	75	135	147	317	152	196	268	443	660	829	1,015	1,397	1,664
Cost of revenue	—	—	—	—	—	—	—	—	31	10	46	43	81	139	192	159	229	292
Gross profit	—	—	—	—	—	—	—	—	285	142	150	224	362	521	637	856	1,168	1,371
Research and development	57	52	58	70	97	80	93	151	151	150	141	34	36	67	76	79	81	102
Selling, general and administrative	15	15	18	25	32	36	40	46	54	61	77	46	50	144	149	154	207	238
Operating income	−58	−54	−20	−54	−80	−63	−27	−83	81	−69	−68	144	276	268	338	551	469	597
Interest expense	—	—	0	0	3	6	5	20	22	18	12	20	8	17	19	18	18	20
Net interest income	0	0	0	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Income before tax	—	—	—	—	—	−68	−32	−102	62	−80	−72	129	249	249	348	557	467	583
Income tax	—	—	—	—	—	0	0	1	−1	1	−0	0	−154	47	67	113	150	170
Net income	−58	−53	−20	−54	−83	−68	−32	−103	63	−80	−72	129	403	202	282	444	317	414
Diluted EPS	−$0.67	−$0.56	−$0.19	−$0.48	−$0.74	−$0.56	−$0.25	−$0.81	$0.45	−$0.56	−$0.50	$0.91	$2.74	$1.44	$2.10	$3.43	$2.56	$3.38
Diluted shares (average)	—	—	103m	111m	113m	123m	127m	128m	139m	144m	144m	141m	147m	141m	134m	129m	124m	122m
EBITDA	−57	−53	−19	−53	−79	−61	−26	−81	83	−67	−64	148	279	274	349	562	480	612

US$ millions unless shown otherwise. Fiscal quarters.

Halozyme Therapeutics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	290	298	265	326	354	452	377	481
Cost of revenue	49	42	48	46	55	79	79	79
Gross profit	241	256	216	279	299	373	297	402
Research and development	18	20	15	18	17	32	26	28
Selling, general and administrative	41	42	42	42	46	77	58	57
Operating income	163	176	142	202	218	−93	185	288
Interest expense	5	5	5	4	4	5	6	6
Income before tax	165	178	144	205	219	−101	180	285
Income tax	28	41	26	40	44	41	30	55
Net income	137	137	118	165	175	−142	150	230
Diluted EPS	$1.05	$1.06	$0.93	$1.33	$1.43	−$1.12	$1.22	$1.90
EBITDA	166	178	144	205	221	−90	189	292

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ALKS vs HALO HALO vs INSM HALO vs MDGL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Halozyme Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Halozyme Therapeutics, Inc.